The Pharma Data

DECEMBER 9, 2020

Some problems, she said, are related to an overactive immune response — such as Guillain-Barre syndrome, where the immune system attacks the body’s nerves. Finally, Anand said, it’s possible the virus itself invades the central nervous system in some patients. The findings, published Dec.

Hospitals 52

Hospitals Doctors Immune Response Nurses 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., 35 — Have chronic kidney disease — Have diabetes — Have immunosuppressive disease — Are currently receiving immunosuppressive treatment — Are ?65

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 17, 2020

About casirivimab and imdevimab Casirivimab and imdevimab (formerly known as REGN-COV2 or REGEN-COV2) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Have chronic kidney disease.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 24, 2020

Centers for Disease Control and Prevention stressed that Americans who get a shot shouldn’t be surprised if they feel under the weather for a few days afterwards. “These are immune responses, so if you feel something after vaccination, you should expect to feel that. Meanwhile, U.S. Worsening spread.

Vaccine 52

Vaccine Virus Immune Response Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos , M.D.,

FDA 40

FDA Clinical Trials Hospitals Government 40

The Pharma Data

DECEMBER 31, 2020

Centers for Disease Control and Prevention — could be somewhat low. Right now, most shots are being given at hospitals, clinics and nursing homes, but Perna and Slaoui agreed that the pace of vaccination should pick up considerably once doses are given out by the major pharmacy chains. million, the Times said.

Vaccine 52

Vaccine Long-Term Care Facilities Virus Hospitals 52